Floatz logo

VEMURAFENIB

Melanoma

Cancer Research UKSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
65/ 100

Competitive context

449 Active assets in the Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Temsirolimus
University of Regensburg
Phase 2BB

View all 50 →

Same molecule, other indications

VEMURAFENIB is also rated in:

metastatic melanomaDormant
B
Indicative ·
63 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →